bearish
China Healthcare Weekly (Jul.7) - New NRDL Negotiation Rules, Assisted Reproduction Payment, Kintor
424 Views09 Jul 2023 09:48
Investors should not be overly optimistic about the new NRDL negotiation rule of innovative drug. Assisted reproduction technology will be covered by medical insurance. We analyzed key flaws of Kintor
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Population Policies Impact on Healthcare Companies Series - Part 118 Jul 2023
- China Healthcare Weekly (Jul.14)-TCM Demand Switch, 8% Benchmark Growth Rate, GLP-1 Change Game Rule16 Jul 2023
- Moderna Inc (MRNA US) - What Would Happen After Moderna Enters China?12 Jul 2023
- China Healthcare Weekly (Jul.7) - New NRDL Negotiation Rules, Assisted Reproduction Payment, Kintor09 Jul 2023
- China Healthcare Weekly (Jun.30)-Surgical Robots, Medical Equipment New Policy, Pfizer's Frustration02 Jul 2023
- China Healthcare Weekly (Jun.23) - National TCM VBP Results, CDE Changes Game Rule, Hua Medicine25 Jun 2023
- Pre-IPO Kelun Biotech (PHIP Updates) - Some Points Worth the Attention07 Jun 2023
x